Morpholine → HCID 71252539, Verbindung
Reaktionsgleichung
C(OC([N:8]([C:40](OC(C)(C)C)=O)[C:9](=[O:39])[C:10]1[CH:15]=[C:14]([N:16]2[CH2:20][CH2:19][CH2:18][C:17]2=[O:21])[CH:13]=[CH:12][C:11]=1[C:22]([N:24]1[CH2:29][CH2:28][N:27]([C:30]2[C:35]([CH3:36])=[CH:34][C:33]([CH2:37][CH3:38])=[CH:32][N:31]=2)[CH2:26][CH2:25]1)=[O:23])=O)(C)(C)C.N1C[CH2:51][O:50][CH2:49][CH2:48]1>>[CH2:37]([C:33]1[CH:34]=[C:35]([CH3:36])[C:30]([N:27]2[CH2:28][CH2:29][N:24]([C:22]([C:11]3[CH:12]=[CH:13][C:14]([N:16]4[CH2:20][CH2:19][CH2:18][C:17]4=[O:21])=[CH:15][C:10]=3[C:9]([N:8]3[CH2:40][CH2:51][O:50][CH2:49][CH2:48]3)=[O:39])=[O:23])[CH2:25][CH2:26]2)=[N:31][CH:32]=1)[CH3:38]Komponenten
3
Versuchsvorschrift
Using N,N-di-tert-butyloxycarbonyl-2-[4-(5-ethyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]-5-(2-oxopyrrolidin-1-yl)benzamide (70 mg) described in Example 809 and morpholine (41 μL) and by the reaction and treatment in the same manner as in Example 770, the title compound (19 mg) was obtained.
Quellen und Nachweise
- ORD-Eintrag
- ord-b74fe8172eb740e38a1358de36c00447
- Quelldatensatz
- uspto-grants-2014_08
- Patentnummer
- US08816079B2
Notizen zur Reaktion
Wird geladen…